Dr Fatiha Tabet

Contact Details

Phone: +61 2 9385 1599
Email: f.tabet@unsw.edu.au

Tabs

Main

2015 – Present: Senior Lecturer/ National Heart Foundation Future Leader Fellow (Faculty of Medicine UNSW)

2013 – 2014: Lecturer (Faculty of Medicine UNSW)

2011 – Present: Conjoint Senior Lecturer (Faculty of Medicine University of Sydney)

2007 – 2012: Post-Doctoral Research Fellow (Heart Research Institute - Faculty of Medicine, University of Sydney)

University role:

Senior Lecturer

Grants:

2014 – 2018: Future Leader Fellowship – Australian National Heart Foundation

2018: Diabetes Australia Research Program Grant – Chief Investigator B

2009 – 2012: Post-doctoral Fellowship – Canadian Institutes of Health Research

2005 – 2008: Canada Graduate Scholarship (CGS) Doctoral Award - Canadian Institutes of Health Research (Top ranking)

2005 – 2007: Doctoral Scholarship - Natural Sciences and Engineering Research Council (Government of Canada -Declined)

2005 – 2007: Doctoral Scholarship - Heart and Stroke Foundation of Canada (Government of Canada, Declined)

2005: Ph.D. Excellence Scholarship - Department of Pharmacology University of Montréal

2003 – 2005: Master’s Scholarship - Canadian Institutes of Health Research/Canadian Hypertension Society/Pfizer Rx&D (Government of Canada)

2002 – 2003: Master’s Scholarship - Québec Hypertension Society, Canada

2002: Master’s Scholarship - University of Montréal, Québec, Canada

Awards:

2015: Best Presentation Award and Travel Award at the 4^th International Conference on Lipoprotein Metabolism and Atherosclerosis. Seoul Korea.

2015: Finalist- Irvine H. Page Young Investigator Research Award. Arteriosclerosis, Thrombosis and Vascular Biology 2015 Scientific Session. San Francisco, US.

2013: Contributing to Australian Scholarship and Science Early Career Researcher Travel Grant to attend the Keystone Symposia: Noncoding RNA in Development and Cancer. Vancouver, British Columbia, Canada

2012: National Heart Foundation Travel Grant- American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2012 Scientific Sessions and the ATVB HDL Workshop Meeting- Chicago, Illinois, United States

2012: International Symposium on Atherosclerosis Asia Pacific Federation Educational Grant. XVI International Symposium on Atherosclerosis Meeting- Sydney NSW Australia

2012: Young Investigator Award- XVI International Symposium on Atherosclerosis Meeting- Sydney NSW Australia

2011: Postdoctoral Oral Award for Excellence in Vascular Research. Australian Vascular Biology Society Scientific Meeting- Bowral NSW Australia

2010: The Ross Hohnen Young Achiever Award for the best Paper by a Post-doctoral Scientist. The Heart Research Institute Awards for Excellence Annual Diner- Sydney, NSW, Australia

2010: Best Post-Doctoral Poster Presentation at the Gordon Conference on Lipoprotein Metabolism. Waterville Valley- New Hampshire, USA

2009: Travel award for the English Session of the 41st Japan Atherosclerosis Society Annual Meeting. Shimonoseki City, Japan

2009: Young Investigator Award from the International Symposium on Atherosclerosis- Boston, USA

2009: Educational Grant by the Asia Pacific Federation in the International Atherosclerosis Society- Boston, USA

2009: Post-doctoral travel award from the Australian atherosclerosis Society- Boston, USA

2006: Ph.D. Best Presentation Award- National Research Forum for Young Investigators in Circulatory and Respiratory Health- Winnipeg, Manitoba, Canada

2006: National Research Forum for Young Investigators in Circulatory and Respiratory Health Travel Award- Winnipeg, Manitoba, Canada

2005: Ph.D. Best Presentation Award- “Fonds de la Recherche en Santé du Québec”. IRCM Student Day, Montréal, Québec, Canada

2004: Ph.D. Best Presentation Award- Canadian Hypertension Society Annual Meeting, Calgary, Alberta, Canada

2004: Educational Support Award- Canadian Hypertension Society Annual Meeting, Calgary, Alberta, Canada

2004: Québec Hypertension Society Travel Award for the 20^th Scientific Meeting of the International Society of Hypertension - Sao Paulo, Brazil

2004: National Research Forum for Young Investigators in Circulatory and Respiratory Health Travel Award- Winnipeg, Manitoba, Canada

2003: Master’s Best Presentation Award- University of Montréal Research Day, Montréal, Québec, Canada

2003: Inter-American Society of Hypertension /National Heart, Lung and Blood Institute Travel Award- San Antonio, Texas, USA

2002: Master’s Award of Excellence - University of Montréal, Québec, Canada

2000: Merck Frost Canada & Co. Travel Award - Canadian Hypertension Society Annual Meeting

Research

Research activities:

Dr Fatiha Tabet research focuses on lipoprotein biology and pathophysiology. In particular, Dr Fatiha Tabet is interested in understanding (i) the functional roles of the microRNA cargo on lipoproteins in cardiovascular disease, diabetes and obesity, (ii) the regulation of lipoproteins, including Lipoprotein (a) and high-density lipoproteins, by microRNAs, (iii) the pathophysiology of lipoproteins and (iv) the role of lipid lowering therapies in determining the levels of lipoproteins. These are exciting new fields of research with enormous potential. Outcomes from her most recent research findings have revealed novel short-non-coding RNA targets with enhanced potential to be manipulated for treating and/or preventing cardiovascular disease.

Publications related to this Person

Book Chapters

Tabet F; Touyz RM, 2007, 'Reactive Oxygen Species, Oxidative Stress, and Vascular Biology in Hypertension', in Comprehensive Hypertension, pp. 337 - 347, http://dx.doi.org/10.1016/B978-0-323-03961-1.50033-7

Journal articles

Tabet F; Torres LFC; Ong KL; Shrestha S; Choteau SA; Barter PJ; Clifton P; Rye KA, 2016, 'High-density lipoprotein-associated miR-223 is altered after diet-induced weight loss in overweight and obese males', PLoS ONE, vol. 11, http://dx.doi.org/10.1371/journal.pone.0151061

Sultana A; Cochran BJ; Tabet F; Patel M; Torres LC; Barter PJ; Rye K-A, 2016, 'Inhibition of inflammatory signaling pathways in 3T3-L1 adipocytes by apolipoprotein A-I', The FASEB Journal, vol. 30, pp. 2324 - 2335, http://dx.doi.org/10.1096/fj.201500026r

Barter PJ; Tabet F; Rye KA, 2015, 'Reduction in PCSK9 levels induced by anacetrapib: an off-target effect?', Journal of lipid research, vol. 56, pp. 2045 - 2047, http://dx.doi.org/10.1194/jlr.C063768

Bisoendial R; Tabet F; Tak PP; Petrides F; Torres LFC; Hou L; Cook A; Barter PJ; Weninger W; Rye KA, 2015, 'Apolipoprotein A-I Limits the Negative Effect of Tumor Necrosis Factor on Lymphangiogenesis', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 35, pp. 2443 - 2450, http://dx.doi.org/10.1161/ATVBAHA.115.305777

Vickers KC; Landstreet SR; Levin MG; Shoucri BM; Toth CL; Taylor RC; Palmisano BT; Tabet F; Cui HL; Rye KA, 2014, 'MicroRNA-223 coordinates cholesterol homeostasis', Proceedings of the National Academy of Sciences of the United States of America, vol. 111, pp. 14518 - 14523, http://dx.doi.org/10.1073/pnas.1215767111

Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR, 2014, 'Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor d', Journal of the American College of Cardiology, vol. 63, pp. 2365 - 2373, http://dx.doi.org/10.1016/j.jacc.2014.02.538

Tabet F; Vickers KC; Cuesta Torres LF; Wiese CB; Shoucri BM; Lambert G; Catherinet C; Prado-Lourenco L; Levin MG; Thacker S, 2014, 'HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells', Nature Communications, vol. 5, http://dx.doi.org/10.1038/ncomms4292

Wu BJ; Ong KL; Shrestha S; Chen K; Tabet F; Barter PJ; Rye K-A, 2014, 'Inhibition of Arthritis in the Lewis Rat by Apolipoprotein A-I and Reconstituted High-Density Lipoproteins', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, pp. 543 - 551, http://dx.doi.org/10.1161/atvbaha.113.302832

Vickers KC; Rye KA; Tabet F, 2014, 'MicroRNAs in the onset and development of cardiovascular disease', Clinical Science, vol. 126, pp. 183 - 194, http://dx.doi.org/10.1042/CS20130203

Huijgen R; Boekholdt SM; Arsenault BJ; Bao W; Davaine JM; Tabet F; Petrides F; Rye KA; DeMicco DA; Barter PJ, 2013, 'Erratum: Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) Trial (Journal of the American College of Cardiology (2012) 59 (1778-1784))', Journal of the American College of Cardiology, vol. 61, pp. 1751, http://dx.doi.org/10.1016/j.jacc.2013.04.002

Huijgen R; Boekholdt SM; Arsenault BJ; Bao W; Davaine JM; Tabet F; Petrides F; Rye KA; Demicco DA; Barter PJ, 2012, 'Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: A nested case-control study', Journal of the American College of Cardiology, vol. 59, pp. 1778 - 1784, http://dx.doi.org/10.1016/j.jacc.2011.12.043

Tabet F; Lambert G; Cuesta Torres LF; Hou L; Sotirchos I; Touyz RM; Jenkins AJ; Barter PJ; Rye KA, 2011, 'Lipid-free apolipoprotein A-I and discoidal reconstituted high-density lipoproteins differentially inhibit glucose-induced oxidative stress in human macrophages', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, pp. 1192 - 1200, http://dx.doi.org/10.1161/ATVBAHA.110.222000

Briones AM; Tabet F; Callera GE; Montezano AC; Yogi A; He Y; Quinn MT; Salaices M; Touyz RM, 2011, 'Differential regulation of Nox1, Nox2 and Nox4 in vascular smooth muscle cells from WKY and SHR', Journal of the American Society of Hypertension, vol. 5, pp. 137 - 153, http://dx.doi.org/10.1016/j.jash.2011.02.001

Nobécourt E; Tabet F; Lambert G; Puranik R; Bao S; Yan L; Davies MJ; Brown BE; Jenkins AJ; Dusting GJ, 2010, 'Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, pp. 766 - 772, http://dx.doi.org/10.1161/ATVBAHA.109.201715

Tabet F; Remaley AT; Segaliny AI; Millet J; Yan L; Nakhla S; Barter PJ; Rye KA; Lambert G, 2010, 'The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, pp. 246 - 252, http://dx.doi.org/10.1161/ATVBAHA.109.200196

Fryirs MA; Barter PJ; Appavoo M; Tuch BE; Tabet F; Heather AK; Rye KA, 2010, 'Effects of high-density lipoproteins on pancreatic β-cell insulin secretion', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, pp. 1642 - 1648, http://dx.doi.org/10.1161/ATVBAHA.110.207373

Rye KA; Bursill CA; Lambert G; Tabet F; Barter PJ, 2009, 'The metabolism and anti-atherogenic properties of HDL', Journal of Lipid Research, vol. 50, http://dx.doi.org/10.1194/jlr.R800034-JLR200

Tabet F; Rye KA, 2009, 'High-density lipoproteins, inflammation and oxidative stress', Clinical Science, vol. 116, pp. 87 - 98, http://dx.doi.org/10.1042/CS20080106

Tabet F; Schiffrin EL; Callera GE; He Y; Yao G; Östman A; Kappert K; Tonks NK; Touyz RM, 2008, 'Redox-sensitive signaling by angiotensin II involves oxidative inactivation and blunted phosphorylation of protein tyrosine phosphatase SHP-2 in vascular smooth muscle cells from SHR', Circulation Research, vol. 103, pp. 149 - 158, http://dx.doi.org/10.1161/CIRCRESAHA.108.178608

Sontia B; Montezano ACI; Paravicini T; Tabet F; Touyz RM, 2008, 'Downregulation of renal TRPM7 and increased inflammation and fibrosis in aldosterone-infused mice: Effects of magnesium', Hypertension, vol. 51, pp. 915 - 921, http://dx.doi.org/10.1161/HYPERTENSIONAHA.107.100339

Savoia C; Tabet F; Yao G; Schiffrin EL; Touyz RM, 2005, 'Negative regulation of RhoA/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: Role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats', Journal of Hypertension, vol. 23, pp. 1037 - 1045, http://dx.doi.org/10.1097/01.hjh.0000166845.49850.39

Tabet F; Schiffrin EL; Touyz RM, 2005, 'Mitogen-activated protein kinase activation by hydrogen peroxide is mediated through tyrosine kinase-dependent, protein kinase C-independent pathways in vascular smooth muscle cells: Upregulation in s', Journal of Hypertension, vol. 23, pp. 2005 - 2012, http://dx.doi.org/10.1097/01.hjh.0000185715.60788.1b

Tabet F; Savoia C; Schiffrin EL; Touyz RM, 2004, 'Differential calcium regulation by hydrogen peroxide and superoxide in vascular smooth muscle cells from spontaneously hypertensive rats', Journal of Cardiovascular Pharmacology, vol. 44, pp. 200 - 208, http://dx.doi.org/10.1097/00005344-200408000-00009

Touyz RM; Chen X; Tabet F; Yao G; He G; Quinn MT; Pagano PJ; Schiffrin EL, 2002, 'Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: Regulation by angiotensin II', Circulation Research, vol. 90, pp. 1205 - 1213, http://dx.doi.org/10.1161/01.RES.0000020404.01971.2F

Conference Papers

Touyz RM; Cruzado M; Tabet F; Yao G; Salomon S; Schiffrin EL, 2003, 'Redox-dependent MAP kinase signaling by Ang II in vascular smooth muscle cells: Role of receptor tyrosine kinase transactivation', in Canadian Journal of Physiology and Pharmacology, pp. 159 - 167, http://dx.doi.org/10.1139/y02-164

Touyz RM; Tabet F; Schiffrin EL, 2003, 'Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension', in Clinical and Experimental Pharmacology and Physiology, pp. 860 - 866, http://dx.doi.org/10.1046/j.1440-1681.2003.03930.x